Back

Genotype, phenotype and outcomes of patients with hypertrophic cardiomyopathy referred for ablation of ventricular tachycardia

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Ventricular tachycardia 3 Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Augusto Meretta

Leiden University Medical Center, Leiden (Netherlands (The))

8 More presentations in this session

Presentation thumbnail
Modification of deceleration zones and late potentials after ventricular tachycardias substrate ablation
Doctor P. China (Mestre-Venice, IT)
Abstract Slides Video
Presentation thumbnail
An optimized multisource acquisition and registration workflow for imaging guided ventricular tachycardia ablation
Doctor M. Parollo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Lower dose radiotherapy did not alter cardiac function and was not pro-arrhythmic: results of the small prospective HALO trial
Mr W. Hoeksema (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
The evaluation of the efficacy of automated peak frequency annotation algorithm for the identification of critical isthmus of ventricular tachycardia and deceleration zones
Professor H. Yorgun (Ankara, TR)
Abstract Slides Video
Presentation thumbnail
Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED-Registry)
Doctor J. van den Bruck (Cologne, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular tachycardia 3

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
Nationwide trends in utilization and safety of ventricular arrythmia ablation in patients with hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Electrical storm in patients with hypertrophic cardiomyopathy
thumbnail
Congress Presentation
The influence of genotype on the phenotype and prognosis of patients with hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources